"Valproic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of voltage dependent sodium channels.
| Descriptor ID |
D014635
|
| MeSH Number(s) |
D02.241.081.944.509.900 D10.251.400.895.593.900
|
| Concept/Terms |
Valproic Acid- Valproic Acid
- Propylisopropylacetic Acid
- 2-Propylpentanoic Acid
- 2 Propylpentanoic Acid
- Divalproex
Divalproex Sodium- Divalproex Sodium
- Semisodium Valproate
- Valproic Acid, Sodium Salt (2:1)
|
Below are MeSH descriptors whose meaning is more general than "Valproic Acid".
Below are MeSH descriptors whose meaning is more specific than "Valproic Acid".
This graph shows the total number of publications written about "Valproic Acid" by people in this website by year, and whether "Valproic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 2 | 2 | 4 |
| 2013 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Valproic Acid" by people in Profiles.
-
Pitt B, Sutton NR, Wang Z, Goonewardena SN, Holinstat M. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. Eur J Pharmacol. 2021 May 05; 898:173988.
-
Spiegel DR, Samaras A, Oldham CL, Kaloji M, Warren A, Maj S, Husain SR, Solomons JI, Le S. A Likely Case of Limbic Encephalitis in a Patient With Voltage-Gated Potassium Channel Complex Antibody, Without a Known Antigenic Target: A Review of the Disease State and Value of Antibody Titers. Psychosomatics. 2017 Nov - Dec; 58(6):669-675.
-
Sofi A, Herial NA, Ali II. Valproate-induced hyperacute hyperammonemic coma in a patient with hypocarnitinemia. Am J Ther. 2013 Nov-Dec; 20(6):e703-5.
-
Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010 Aug; 67(8):793-802.
-
Kidd SK, Schneider JS. Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Res. 2010 Oct 1; 1354:172-8.
-
Lovell BV, Marmura MJ. Valproate semisodium ER for migraine and cluster headache prophylaxis. Expert Opin Drug Metab Toxicol. 2010 Apr; 6(4):495-504.
-
Debeb BG, Xu W, Mok H, Li L, Robertson F, Ueno NT, Reuben J, Lucci A, Cristofanilli M, Woodward WA. Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys. 2010 Mar 1; 76(3):889-95.
-
Kelly MP, Logue SF, Dwyer JM, Beyer CE, Majchrowski H, Cai Z, Liu Z, Adedoyin A, Rosenzweig-Lipson S, Comery TA. The supra-additive hyperactivity caused by an amphetamine-chlordiazepoxide mixture exhibits an inverted-U dose response: negative implications for the use of a model in screening for mood stabilizers. Pharmacol Biochem Behav. 2009 Jun; 92(4):649-54.
-
Piovesan EJ, Randunz V, Utiumi M, Lange MC, Kowacs PA, Mulinari RA, Oshinsky M, Vital M, Sereniki A, Fernandes AF, e Silva LL, Werneck LC. Influence of NMDA and non-NMDA antagonists on acute and inflammatory pain in the trigeminal territory: a placebo control study. Arq Neuropsiquiatr. 2008 Dec; 66(4):837-43.
-
Pascual J, Láinez MJ, Dodick D, Hering-Hanit R. Antiepileptic drugs for the treatment of chronic and episodic cluster headache: a review. Headache. 2007 Jan; 47(1):81-9.